Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No HPO annotations are available for this condition.
Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) is defined by complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis, epicanthus inversus, and telecanthus. Two types of BPES have been described :
BPES type I includes the four major features and female infertility caused by primary ovarian insufficiency.
No consensus clinical diagnostic criteria for blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) have been published.
BPES should be suspected in individuals with the following clinical findings and family history. Major clinical findings, all present at birth:
Blepharophimosis. Narrowing of the horizontal aperture of the eyelids
No approved treatments are currently available for telecanthus. The disease remains an area of unmet medical need.
No clinical practice guidelines for blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with BPES, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 2. Recommended Evaluations Following Initial Diagnosis in Individuals with BPES
Table 4.
Recommended Surveillance for Individuals with BPES
System/Concern | Evaluation | Frequency
Eyelid
malformation | Ophthalmic follow up | Based on person's age, past procedures, results of visual acuity testing
POI | • Endocrinologic gynecologic follow up to monitor ovarian status
No clinical trials have been registered for telecanthus.
31 publications have been identified in PubMed for telecanthus. Research spans Case Report / Case Series (67%), Basic Science / Preclinical (17%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 20 | 67% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:30 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
BPES type II includes only the four major features.
Complex eyelid malformation
Source: GeneReviews — "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome"
Epicanthus inversus. A skin fold arising from the lower eyelid and running inward and upward
Telecanthus. Lateral displacement of the inner canthi and the inferior punctum with normal interpupillary distance
Source: GeneReviews — "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome"
Because of its characteristic phenotype and the absence of extraocular manifestations other than primary ovarian insufficiency, BPES can be distinguished relatively easily from other conditions in which ptosis or blepharophimosis is a major feature (e.g., NR2F2-associated 46,XX sex reversal 5 [OMIM 618901] and Say-Barber-Biesecker variant of Ohdo syndrome [see KAT6B Disorders]).
Source: GeneReviews — "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome"
System/Concern | Evaluation | Comment |
|---|---|---|
malformation | Exam byophthalmologist oculoplasticsurgeon | Assess for size of palpebral apertures, lacrimal duct abnormality, eyelid elevation. Vision |
POI | Eval by pediatricianor endocrinologist/gynecologist | For females w/BPES during late childhood or early puberty to assess gonadal function assess/discuss onset course of POI; See also . Genetic |
counseling | By geneticsprofessionals1 | To inform affected persons their families re nature, MOI, implications of BPES to facilitate medical personal decision making; In females w/BPES, family history can indicate type of BPES (type I inferred by assoc w/subfertility or infertility). |
Treatment of Manifestations in Individuals with BPES Manifestation/Concern | Treatment | Considerations/Other |
Eyelid malformation | Surgery | Traditionally performed in 2 stages:; Age 3-5 yrs: medial canthoplasty for correction of blepharophimosis, epicanthus inversus, telecanthus; ~1 yr later: ptosis correction, usually requiring brow suspension procedure |
POI | Standard mgmt for POI (not specific to BPES)1 | Typically consisting of:; Hormone replacement therapy; Monitoring optimizing bone health; Eval of options for parenthood (adoption, foster parenthood, embryo donation, egg donation, ovary cryopreservation) Psychological support is important. POI = primary ovarian insufficiency 1. |
Recommended Surveillance for Individuals with BPES System/Concern | Evaluation | Frequency Eyelid |
malformation | Ophthalmic follow up | Based on person's age, past procedures, results of visual acuity testing POI |
Source: GeneReviews — "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome"
View trials for telecanthus
Assess effects of hormone replacement therapy for adjustments as needed.
Psychological follow up
| Individualized, but at least annually
POI = primary ovarian insufficiency
Source: GeneReviews — "Blepharophimosis, Ptosis, and Epicanthus Inversus Syndrome"
5 |
17% |
Research summaries | 4 | 13% |
Clinical study results | 1 | 3% |
Bothra N (2026). [PMID: 41498299](https://pubmed.ncbi.nlm.nih.gov/41498299/). *Orbit (Amsterdam, Netherlands)*. [Case Report / Case Series]
Wojciechowska J (2026). [PMID: 42018266](https://pubmed.ncbi.nlm.nih.gov/42018266/). *Ophthalmol Ther*. [Review / Meta-Analysis]
Panneerselvam E (2026). [PMID: 41971499](https://pubmed.ncbi.nlm.nih.gov/41971499/). *J Maxillofac Oral Surg*. [Case Report / Case Series]
Kim S (2026). [PMID: 41804817](https://pubmed.ncbi.nlm.nih.gov/41804817/). *American journal of medical genetics. Part A*. [Case Report / Case Series]
Neuhouser AJ (2026). [PMID: 37276318](https://pubmed.ncbi.nlm.nih.gov/37276318/). *Unknown Journal*. [Review / Meta-Analysis]
Jamin C (2026). [PMID: 41662209](https://pubmed.ncbi.nlm.nih.gov/41662209/). *Journal of visualized experiments : JoVE*. [Basic Science / Preclinical]
Tripathy K (2026). [PMID: 32809540](https://pubmed.ncbi.nlm.nih.gov/32809540/). *Unknown Journal*. [Review / Meta-Analysis]
Dighe R (2025). [PMID: 41018437](https://pubmed.ncbi.nlm.nih.gov/41018437/). *Cureus*. [Case Report / Case Series]
Zgheib O (2025). [PMID: 39887729](https://pubmed.ncbi.nlm.nih.gov/39887729/). *Clinical genetics*. [Case Report / Case Series]
Attar A (2025). [PMID: 40233639](https://pubmed.ncbi.nlm.nih.gov/40233639/). *International journal of surgery case reports*. [Case Report / Case Series]